梅特福林对与年龄相关的黄斑退化症的潜在有效性:系统性审查和元分析
Matthew D Huh1,2, Simon N Le1, Kieran S O'Brien1,3
1Department of Ophthalmology, University of California, San Francisco, San Francisco, California.
Ophthalmology science
|April 15, 2025
概括
甲福明可以降低与年龄相关的黄斑变性 (AMD) 的风险. 这次系统性审查发现,在甲福林使用者中,AMD的几率较低,但需要更多的研究.
科学领域:
- 眼科医生 眼科 眼科
- 药理学 药理学是指药理学的学科.
- 老年学是指老年学的学科.
背景情况:
- 甲福明是一种常见的糖尿病药物,具有抗氧化,抗炎和抗血管原性质.
- 这些特性表明,与年龄相关的黄斑变性 (AMD) 有潜在的治疗益处.
研究的目的:
- 系统地审查和分析甲福明在降低与年龄相关的黄斑变性 (AMD) 患病率方面的疗效.
主要方法:
- 我们对Embase,MEDLINE,Cochrane图书馆和Web of Science数据库进行了系统的搜索.
- 包括的研究包括在AMD诊断之前使用口服甲福明的研究;数据使用随机效应模型进行了元分析.
- 亚组分析考虑了研究设计,AMD亚型,性别和美特福林剂量.
主要成果:
- 分析了18项涉及超过260万参与者的观察性研究.
- 甲胺使用与AMD几率显著降低有关 (合并OR=0.86).
- 在糖尿病患者和非糖尿病患者中都观察到保护作用,特别是在较低的甲胺剂量下.
结论:
- 目前的证据表明,甲素对AMD有潜在的保护作用.
- 然而,所有包含的研究都是观察性的,存在偏差风险,特别是混风险.
- 随机临床试验至关重要,以证实甲福林在预防AMD发病方面的有效性.
更多相关视频
08:54Author Spotlight: Understanding Age-Related Macular Degeneration Pathophysiology with QAF Workflow
Published on: May 26, 2023
1.3K
05:14Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
Published on: August 11, 2023
976
相关概念视频
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...